The unprecedented Medicaid disease management deal struck between Florida and Pfizer this summer represents an important "move past unit cost control into total disease control," according to Perry Cohen, PharmD.
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.